CHUNLI MEDICAL(SH:688236) Shang Hai Zheng Quan Bao·2026-01-29 20:26Group 1 - The company expects a significant increase in net profit for the year 2025, projecting a range of CNY 244.99 million to CNY 287.99 million, which represents an increase of CNY 120 million to CNY 163 million compared to the previous year, translating to a year-on-year growth of 96.01% to 130.41% [3] - The net profit attributable to the parent company, excluding non-recurring gains and losses, is estimated to be between CNY 229.54 million and CNY 269.54 million, indicating an increase of CNY 135 million to CNY 175 million from the previous year, with a year-on-year growth of 142.80% to 185.11% [3] - The previous year's net profit attributable to the parent company was CNY 124.99 million, with a net profit excluding non-recurring gains and losses of CNY 94.54 million [4] Group 2 - The substantial growth in net profit is attributed to the gradual release of growth potential from various product lines following their inclusion in centralized procurement, as well as the company's ongoing international development strategy and improved operational management [6] - The company has communicated with its auditing firm regarding the performance forecast, and there are no significant discrepancies between the company and the auditors concerning the forecast [3]